



Press Release

Vitalife Life Sciences Ventures Closes \$50 Million Fund

Tel Aviv, Israel: April 13, 2003 – Vitalife, the Israeli life sciences venture capital fund, today announced the closing of its first fund, totaling \$50 million. HarbourVest Partners, one of the world's leading private equity firms joins Vitalife's existing investors that include Discount Capital Markets and Investments, SCP Private Equity Partners, Boston Scientific and Evergreen.

Vitalife had its initial closing of approximately \$30 million during the first quarter of 2002. Its Managing Partners are Professor Avi Ludomirsky M.D. and Jeff Dykan. Vitalife focuses on investments in Israeli and Israel-related companies in the healthcare and life sciences fields. Its portfolio companies include MediGuide, SightLine, Procognia and TransPharma.

Professor Ludomirsky, Vitalife's Managing Partner, said: "It is a great achievement for Vitalife that world-class investors such as HarbourVest have decided to join our fund, especially given the current investment climate. Their investment attests to the quality of Vitalife's portfolio companies, our "hands-on" management capabilities and the excellent deal flow potential in the Israeli life sciences field".

For additional details:

Please contact Dorit Katzir: Tel.: +972-3-561-1424 ext 134